 |
| A handout photo shows vials during the production of “Gam-COVID-Vac” vaccine against the coronavirus disease (COVID-19), developed by the Gamaleya National Research Institute of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), at Binnopharm pharmaceutical company in Zelenograd near Moscow, Russia August 7, 2020. Picture taken August 7, 2020. The Russian Direct Investment Fund (RDIF)/Andrey Rudakov/Handout via REUTERS ATTENTION EDITORS – THIS IMAGE WAS PROVIDED BY A THIRD PARTY. NO RESALES. NO ARCHIVES. MANDATORY CREDIT. |
Siberiaโs Vector virology institute on Tuesday completed early-stage human trials, known as Phase II, of a second potential Russian vaccine against COVID-19, the state consumer safety watchdog was cited by the Interfax news agency as saying.
Russia registered its first vaccine candidate, developed by Moscowโs Gamaleya Institute, in August. Late-stage trials of this vaccine, due to involve 40,000 participants, were launched last week.
Human trials of the second potential COVID-19 vaccine, a peptide-based jab, began on July 27 and involved a group of 100 volunteers, Interfax cited watchdog Rospotrebnadzor as saying.
โToday โฆ the final group of 20 volunteers was released from hospital,โ said in a statement. โAll 100 volunteers were vaccinated with two doses and have completed a 23-day monitoring period in hospital. The volunteers are feeling good.โ
Results are due to be published on Sept. 30, Interfax said.
